Abstract:Imbalance miRNAs contribute to tumor formation; therefore, the development of small-molecule compounds that regulate miRNA biogenesis is an important strategy in oncotherapy. Here, (−)-Gomisin M1 (GM) was found to modulate miRNA biogenesis to inhibit the proliferation, migration, and invasion of hepatocellular carcinoma (HCC) cells. GM modulated expression profiles of miRNA and protein in HCC cells and suppressed tumor growth in a mouse model. Mechanistically, GM affected miRNA maturation by targeting TAR RNA-binding protein 2 (TRBP), with an efficacy higher than that of enoxacin, and promoted the binding of TRBP with Dicer. Structural simplification and a preliminary structure–activity relationship study via the synthesis of 20 GM derivatives showed that compound 9 exhibited more potent inhibitory activity in HCC cell proliferation and affinity for TRBP than did GM. These results suggest that TRBP may be a novel potential therapeutic target in HCC and compound 9 may be a potential drug candidate for the treatment of HCC.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.1c00018?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c00018</a>.Additional figures illustrating the screening (Figure S1), the activities of GM (Figures S2–S5), miRNAomics and proteomics analysis (Figures S7–S14), the effect of GM on the expression of RISC elements (Figure S15), evidence that GM did not target Dicer or AGO2 (Figure S16), TRBP expression after transfection (Figure S17), activities of compounds 3, 7, 9, and 10 in HeLa-miR-21-luciferase cells (Figure S18), the KD values of compounds 3, 7, 9, and 10 (Figure S19), the activity of GM analogues against SK-Hep-1 cells (Figure S20), a comparison of the activity of GM and compound 9 (Figure S21), and the effect of compound 21 in HeLa-miR-21-luciferase cells (Figure S22), evidence that compound 21 did not target PIWIL3 or TPO2β, miRNAomics and proteomics data (Tables S1–S3), sequences of primers (Tables S4 and S5), NMR spectra, and HPLC data of (−)-Gomisin M1 and 7 (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00018/suppl_file/jm1c00018_si_001.pdf">PDF</a>)Molecular formula strings of GM and 1–21 (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00018/suppl_file/jm1c00018_si_002.csv">CSV</a>)This article has not yet been cited by other publications.

Identification of novel inhibitors of the transcriptional coactivator MRTF-A for HCC therapy

TRAF2 Inhibits Senescence in Hepatocellular Carcinoma Cells Via Regulating the ROMO1/ NAD+/SIRT3/SOD2 Axis.

Inhibitors of Rho/MRTF/SRF Transcription Pathway Regulate Mitochondrial Function

Discovery of a Novel Small-Molecule Inhibitor Disrupting TRBP-Dicer Interaction Against Hepatocellular Carcinoma Via the Modulation of Microrna Biogenesis.

Development of a Potent and Specific FGFR4 Inhibitor for the Treatment of Hepatocellular Carcinoma

Novel mTOR Inhibitor Enhances the Sensitivity of Hepatocellular Carcinoma Cells to Molecular Targeting Agents

Discovery of potent and novel dual NAMPT/BRD4 inhibitors for efficient treatment of hepatocellular carcinoma

Design, synthesis, and biological evaluation of novel 5,7,4'-trimethoxyflavone sulfonamide-based derivatives as highly potent inhibitors of LRPPRC/STAT3/CDK1

Targeting the HuR Oncogenic Role with a New Class of Cytoplasmic Dimerization Inhibitors

Identification and validation of microtubule depolymerizing agent, CYT997, as a potential drug candidate for hepatocellular carcinoma

Anti-tumor and Anti-Metastatic Effects of RRx-001 on Hepatocellular Carcinoma: Mechanisms of Action and Therapeutic Potential

A Novel Inhibitor of MDM2 Oncogene Blocks Metastasis of Hepatocellular Carcinoma and Overcomes Chemoresistance.

Identification and functional validation of miR-190b-5p and miR-296-3p as novel therapeutic attenuators of liver fibrosis

Identification of a Novel TAR RNA-Binding Protein 2 Modulator with Potential Therapeutic Activity against Hepatocellular Carcinoma

Targeting STAT3, FOXO3a, and Pim‐1 kinase by FDA‐approved tyrosine kinase inhibitor–Radotinib: An in silico and in vitro approach

Inhibition of DTYMK significantly restrains the growth of HCC and increases sensitivity to oxaliplatin

Abstract 4867: Treating Hepatocellular Carcinoma Metastasis and Overcoming Chemoresistance Through Inhibiting the MDM2 Oncogene

Identification of a new TRAF6 inhibitor for the treatment of hepatocellular carcinoma

Identification of Pirin as a Molecular Target of the CCG-1423/CCG-203971 Series of Antifibrotic and Antimetastatic Compounds

Comprehensive Omics Analysis of a Novel Small-Molecule Inhibitor of Chemoresistant Oncogenic Signatures in Colorectal Cancer Cell with Antitumor Effects

Discovery of highly potent and selective EGFRT790M/L858R TKIs against NSCLC based on molecular dynamic simulation